Retrospective analyses of patients who received short-hydration cisplatin-based combination chemotherapy were conducted to evaluate the safety and feasibility of this protocol in an outpatient setting. A total of 71 patients with thoracic malignancies (lung cancer, malignant pleural mesothelioma, or thymic cancer) who received short-hydration cisplatin-based combination chemotherapy through the Department of Respiratory Medicine, Kurashiki Central Hospital, from November 2009 to October 2010 were included in this study. The frequency and severity of adverse events and the proportion of patients who were able to progress to outpatient chemotherapy at the second and further cycles of chemotherapy were assessed. Total hydration time was from 220 to 280 min. Total volume was from 1,600 to 2,100 ml. The proportion of patients who suffered from nausea, vomiting, and serum creatinine elevation were 6%, 0%, and 0%, respectively. Among 57 patients who received two or more cycles of treatment, 44 (77%) successfully received the second and further cycles of chemotherapy in an outpatient setting. In conclusion, short-hydration cisplatin-based combination chemotherapy seems to be a safe treatment option that allows patients to receive chemotherapy in an outpatient setting.